Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors

描述(申请人提供)：目前可用于治疗HPV(-)头颈部鳞状细胞癌(HNSCC)的选择非常有限，HNSCC是美国和世界范围内第六大癌症原因。像大多数形式的癌症一样，HNSCC依赖于血管生成，即血管的生长。我们开发了一种模拟的多模多肽，它可以抑制肿瘤血管生成的生长，并直接抑制肿瘤细胞的黏附和迁移。用这种多峰多肽治疗的肿瘤不太可能对治疗产生耐药性，因为它抑制了来自广泛的肿瘤分泌因子的信号。在这个项目中，我们将为这种多肽创造一种新型的靶向纳米颗粒递送载体。这种纳米颗粒包裹的多肽将被系统地给药，并将在肿瘤及其血管中积聚，以提高疗效和安全性。该项目的成功完成将导致创建一种治疗HNSCC的强大的新疗法，并帮助一家初创生物技术公司达到一个关键的里程碑。

DESCRIPTION (provided by applicant): There are very limited options currently available for the treatment of HPV(-) head and neck squamous cell cancer (HNSCC), the sixth leading cause of cancer in the United States and worldwide. HNSCC, like most forms of cancer, is dependent on angiogenesis, the growth of blood vessels. We have developed a mimetic multimodal peptide that inhibits growth of tumor angiogenesis and directly inhibits tumor cell adhesion and migration. Tumors treated with this multimodal peptide are less likely to develop resistance to therapy because it inhibits signals from a broad range of tumor-secreted factors. In this project we will create a novel targeted nanoparticle delivery vehicle for this peptide. The nanoparticle-encapsulated peptide will be administered systemically and will accumulate in the tumor and its vasculature in order to enhance both efficacy and safety. Successful completion of the project will result in the creation of a powerful, new therapeutic for the treatment of HNSCC and also help a startup biotechnology company reach a critical milestone.